MedTrace Logo

Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.

NCT01151462 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-09-23

No results posted yet for this study

Summary

The aim of this study is to investigate short and long term consequences from early postnatal HCMV infection transmitted via human milk in very preterm infants (birth weight \< 1500 g or gestational age \< 32 weeks). These infants are at high risk of early death or survival with chronic disease and neurodevelopmental impairment if infected with HCMV. Infection is a common complication in this group of patients and reported to be the most frequent cause of death after the second week of life. Systemic infection in the newborn period is reported as representing an independent risk factor for survival with neurodevelopmental impairment among very preterm infants.

Conditions

  • Hearing Loss
  • Mental Retardation
  • Microcephaly
  • Chorioretinitis

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Ullevaal University Hospital

    collaborator OTHER

  • University Hospital, Akershus

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Arild Rønnestad, Dr.med (PhD) · Oslo University Hospital

Eligibility

Min Age
1 Week
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-01-31
Completion
2013-05-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151462 on ClinicalTrials.gov